STALICLA completes pre-IND meet with FDA on STP1 for patients with ASD
Category: #health  | By Nikita Chaurasia  | Date: 2019-08-23 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

STALICLA completes pre-IND meet with FDA on STP1 for patients with ASD
  • Atrium Spectrum Disorder (ASD) affects 1 in 59 school children of 8-years in the United States. It is a common neurodevelopmental disorder, with a higher level of heterogeneity.
     
  • Such technologies are used for the first time in the neurodevelopment field and it is a hugely thrilling project with a scope to change path of this specialty.

STALICLA, a biotech company focused on Autism Spectrum Disorder (ASD) based in Switzerland, reportedly announced the completion of pre-Investigational New Drug (IND) meeting with the United States Food and Drug Administration (FDA) about the preparation for the entry of STP1 into clinical trials.

CEO and Founder of STALICLA, Lynn Durham stated that the company is appreciative of strong interest and technical guidance given by FDA in personalized medicine approaches for Autism Spectrum Disorder (ASD) patients.

Durham added that STALICLA is focused to rapidly move ahead with the submission of STP1 Investigational New Drug (IND). STP1 has the potential to be the first precision medicine for a patient subgroup having Autism Spectrum Disorder and thus herald a new future for this field.

ASD affects 1 in 59 school children of 8-years in the United States. It is a common neurodevelopmental disorder, with a higher level of heterogeneity. Eighty percent of patients are considered as idiopathic, with no genetically identifiable cause. Conventionally, drug developers have seen ASD as a single-disease entity, overseeing its biological heterogeneity and clinical complexity.

STP1 is developed by utilizing STALICLA’s systems biology driven platform; DEPI, an integrative framework that utilizes large-scale clinical, pharmacological, molecular and genetic data to define patient subgroups in Autism Spectrum Disorder and to select personalized treatments.

Such technologies are being used for the first time in the neurodevelopment field, and it is a hugely thrilling project with a scope to change path of the specialty.

 

Source Credit: https://venturebeat.com/2019/08/22/stalicla-announces-completion-of-pre-ind-meeting-with-fda-on-stp1-for-subgroup-of-patients-with-autism-spectrum-disorder-asd/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...

Attero aims to increase recycling capacity, plans for IPO in 2025

Attero aims to increase recycling capacity, plans for IPO in 2025

By Nikita Chaurasia

Attero Recycling, a firm that recycles electronic waste, is aiming to launch an initial public offering (IPO) in 2025, according to its Co-Founder and CEO Nitin Gupta. As per Gupta, the company is currently debating whether to list its shares in I...